At a glance
- Originator Merck Sante
- Class Antiplatelets; Phenylacetates; Small molecules; Sulfonamides
- Mechanism of Action Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 30 Mar 1995 Phase-I clinical trials for Thrombosis in France (Unknown route)
- 18 Jan 1995 Preclinical development for Thrombosis in France (Unknown route)